After Exact Sciences announced the appointment of Aaron Bloomer as its incoming CFO, William Blair called Bloomer’s resume “impressive” and said the executive’s experience “seems to fit the bill for what the company was looking for in its next finance leader.” The firm, which is positive on the announcement and believes it gives the company clarity, says Exact remains a top idea among the firm’s life science tools and diagnostics coverage and it keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Appoints Aaron Bloomer as New CFO
- ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
- Exact Sciences to supply individual cancer information to Mayo Clinic patients
- Exact Sciences removed from ‘Tactical Outperform’ list at Evercore ISI
- Citi opens ‘positive catalyst watch’ on Exact Sciences after competitor data